OpGen

OpGen is primarily a lab diagnostic manufacturer focused on identifying and treating bacterial infections. It has the technology to detect pathogens and predict resistance. Through the dual platform offering of the AMR Gene Panel and Unyvero, it can provide diagnostic results in hours instead of days.

Equities

Equities by Sector

Sectors

Thematics

Latest

Inside the mind of investors: International Biotechnology Trust

Borussia Dortmund – executive interviews

UK equities: A generational opportunity?

Audiovisual

Latest

Vantage: Gresham House Energy Storage Fund – Navigating challenges in energy storage

IP Group – executive interview

Georgia Capital in 60 seconds

About Edison

About Edison

Careers

OpGen (NASDAQ: OPGN)

Latest Insights

OpGen — Cash concerns dampen active Q2

OpGen — FIND collaboration advances to development

OpGen — Feasibility milestone from FIND collaboration

OpGen — Optimistic start to kick off a promising year

Sector

Equity Analyst

Key Management

Research

OpGen — Forecasts reset ahead of busy 2023

OpGen — FY22 wrap offers key operational takeaways

OpGen — Interim milestone achieved for R&D collaboration

OpGen — FIND milestone payment triggered

OpGen — New public offering to support funding needs

OpGen — Share consolidation to regain Nasdaq compliance

OpGen: Encouraging top-line data from Unyvero urinary tract infection (UTI) panel

OpGen — Near-term adjustments with outlook unchanged

OpGen — Test menu expansion opportunity with positive data

OpGen — Guidance revision triggered by softer Q322

OpGen — Broadening its commercial footprint in Q322

OpGen — Rapid detection collaboration with BioVersys

OpGen — Unyvero UTI panel approaching final readouts

OpGen — $3.38m raised through private placement

OpGen — Unyvero A30 RQ collaboration with FIND

OpGen — Addressing AMR with next-generation sequencing

OpGen — Re-acceleration with momentum in the back half

OpGen — Another collaboration agreement for Ares Genetics

OpGen — A catalyst-rich Q222

OpGen — Expanding presence in the Middle East

OpGen — Clinical peer-review supports the HPN panel

OpGen — US momentum offset by one-time items

OpGen: Edison Open House Healthcare 2022

OpGen — FDA clearance a step forward

OpGen — AMR Gene Panel clearance expected shortly

OpGen Webinar – A corporate and business update from the front lines of the fight against AMR

OpGen — Q121 results

OpGen — 2020 results

OpGen – Edison Open House interview

OpGen — An increased focus on Unyvero

OpGen — Q220 results

OpGen – executive interview

OpGen — Merger with Curetis closes

OpGen — Shareholder votes on Curetis merger coming

OpGen — First 510(k) filed with the FDA

OpGen — Rapid and effective diagnosis of infection

Further insights

An update on OpGen: Deals, expansion and revenues

Encouraging top-line data from Unyvero urinary tract infection (UTI) panel

Healthcare Week 2023

OpGen: Leadership in the global fight against the AMR pandemic

OpGen CEO Oliver Schacht on OpGen’s $15m capital raise

Nine things investors need to know about OpGen

ASCO 2023 key takeaways

Machine learning in drug development

Outlook for 2023: Biotechs remain central to novel drug development

Oncology ABCs (part four): Blood cancers (AML) – notable innovations

Cell and gene therapies

Drug delivery platforms

Oncology ABCs (part three) – thinking outside the box in women’s cancer

Neuroscience comeback

IPO apocalypse

Oncology ABCs (part two) – vaccines: niche no longer

ESG, moving beyond the box tick